Leering Partners Lifts Disc Medicine, Inc. (IRON) Following EPP Drug NDA Application

Disc Medicine Inc. (NASDAQ:IRON) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Leerink Partners raised its price target of the stock to $115 from $110 while reiterating an Outperform rating.

The price target hike comes after the US Food and Drug Administration accepted the company’s New Drug Application for its lead asset, bitopertin, an oral GlyT-1 inhibitor for erythropoietic protoporphyria (EPP). The company posted topline interim data in the Phase 2 RALLYMF trial in patients with myelofibrosis anemia. The research firm remains confident in the candidate drug’s prospects, with a high probability of success for DISC-0974 in myelofibrosis. Consequently, it has raised the company’s revenue forecast to about $748 million from $359 million.

Analysts at Raymond James have also echoed similar sentiments on raising the stock’s price target to $117 from $108 while reiterating a Strong Buy rating. The price target hike is in response to topline interim data from the RALLY-MF Phase 2 trial in patients with Myelofibrosis (MF) and Anemia presented at ASH 2025.

Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on creating new treatments for serious blood (hematologic) diseases by targeting red blood cell biology, specifically heme production and iron balance.

While we acknowledge the potential of Disc Medicine, Inc. (NASDAQ:IRON) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRON and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.